Back to Search
Start Over
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): 60 week follow-up of the phase III PERSIST-1 trial.
- Authors :
- Mesa, Ruben A.
Egyed, Miklos
Szoke, Anita
Suvorov, Aleksandr
Perkins, Andrew
Mayer, Jiri
Ganly, Peter
Schouten, Harry C.
Tosi, Patrizia
Farber, Charles Michael
Zachee, Pierre
Scheid, Christof
Dean, James P.
Granston, Tanya
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Nangalia, Jyoti
Mead, Adam
Harrison, Claire N.
Mesa, Ruben A.
Egyed, Miklos
Szoke, Anita
Suvorov, Aleksandr
Perkins, Andrew
Mayer, Jiri
Ganly, Peter
Schouten, Harry C.
Tosi, Patrizia
Farber, Charles Michael
Zachee, Pierre
Scheid, Christof
Dean, James P.
Granston, Tanya
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Nangalia, Jyoti
Mead, Adam
Harrison, Claire N.
- Publication Year :
- 2016
Details
- Database :
- OAIster
- Notes :
- English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1364926418
- Document Type :
- Electronic Resource